Positive vascular invasion group | Negative vascular invasion group | p value | ||
---|---|---|---|---|
(n = 13) | (n = 43) | |||
Gender | (male) | 7 (53.9%) | 26 (60.5%) | 0.37 |
(female) | 6 (46.1%) | 17 (39.5%) | ||
Age | (years) | 70 (41–82) | 73 (43–82) | 0.81 |
HBV infectiona | 4 (30.8%) | 15 (34.9%) | 0.78 | |
HCV infectionb | 8 (61.5%) | 26 (60.5%) | 0.94 | |
Recurrence of hepatocellular carcinoma | 5 (38.5%) | 13 (30.2) | 0.58 | |
Aspartate aminotransferase | (IU/dL) | 31 (17–84) | 38 (14–139) | 0.25 |
Alanine aminotransferase | (IU/dL) | 26 (13–55) | 36 (12–157) | 0.26 |
Albumin | (g/dL) | 4.1 (3.0–5.0) | 4.0 (2.8–4.8) | 0.36 |
Total bilirubin | (mg/dL) | 0.72 (0.46–1.46) | 0.72 (0.26–2.12) | 0.94 |
Prothrombin activity | (%) | 100 (82–100) | 100 (68–100) | 0.78 |
Platelets count | (mm4/dL) | 15.3 (5.8–33.9) | 11.5 (4.2–22.7) | 0.08 |
Conventional DCP | (mAU/mL) | 69 (8–3549) | 22 (9–475) | 0.04 |
Next-generation DCP | (mAU/mL) | 74 (17–574) | 30 (16–813) | 0.01 |
Alpha-fetoprotein | (ng/mL) | 9.7 (1.6–1208.7) | 10.6 (1.6–453.2) | 0.58 |
Pathological fibrosis gradec | 0.07 | |||
f1 | 4 | 3 | ||
f2 | 4 | 9 | ||
f3 | 1 | 11 | ||
f4 | 4 | 20 | ||
Pathological hepatitis gradec | 0.33 | |||
a1 | 4 | 13 | ||
a2 | 4 | 15 | ||
a3 | 4 | 15 | ||
a4 | 1 | 0 | ||
Tumor diameter | (mm) | 28 (11–50) | 22 (9–38) | 0.06 |
Tumor differentiation | ||||
Well-differentiated | 0 (0%) | 9 (20.9%) | 0.02 | |
Modelately differentiated | 11 (84.6%) | 30 (76.7%) | 0.81 | |
Poorly differentiated | 2 (15.4%) | 3 (7.0%) | 0.38 | |
Others | 0 | 1 (2.3%) | 0.41 | |
Fibrous capsule infiltration of tumor | 6 (46.2) | 19 (44.2) | 0.89 |